Bladder cancer (BCa) is among the five most common malignancies worldwide. In the US alone, new BCa cases for 2012 are estimated at 73,500 with estimated deaths at 14,880. At presentation, the majority of bladder tumors are non?muscle invasive, and can be treated by transurethral resection of the tumor, however, more than 70% of patients with BCa will have a recurrence during the first two years after diagnosis. This recurrence phenomenon makes BCa one of the most prevalent cancers worldwide. Furthermore, once treated, patients are under continued surveillance with routine cystoscopy for detection of new tumor development, so the healthcare costs of BCa are a major burden. The overall goal of this project is to develop assays that can achieve the accurate, non?invasive detection of BCa via urinalysis. Using high?throughput genomic profiling technologies, we have derived a series of molecular signatures that outperform any currently used urinalysis assay for BCa detection. The first specific aims are designed to validate the diagnostic accuracy of components of these signatures using alternative techniques. The goal is to establish the technical and scientific merit of the approach. Further specific aims will be designed to determine the feasibility of developing selected nucleic acid?based molecular signatures into robust assays with clinical utility. At the end of the proposed study, assays will be ready for development for use in the clinic. The development of non?invasive, urine based assays for bladder cancer detection and disease status evaluation will be of tremendous benefit to both patients and the healthcare system.
Bladder cancer is one of the most prevalent cancers in the world, due partly to its persistent recurrence after initial treatment. The development of accurate assays that can detect and monitor bladder cancer non-invasively through urine analysis would be a major advance over current modalities and would benefit both patients and healthcare systems. The goal of this project is to develop diagnostic assays for bladder cancer that can be commercialized for clinical utility.
|Huang, Sijia; Kou, Lei; Furuya, Hideki et al. (2016) A Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer. Cancer Epidemiol Biomarkers Prev 25:1361-6|
|Urquidi, Virginia; Netherton, Mandy; Gomes-Giacoia, Evan et al. (2016) Urinary mRNA biomarker panel for the detection of urothelial carcinoma. Oncotarget 7:38731-38740|
|Miyake, M; Goodison, S; Lawton, A et al. (2015) Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway. Oncogene 34:890-901|
|Giacoia, Evan Gomes; Miyake, Makito; Lawton, Adrienne et al. (2014) PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation. Mol Cancer Res 12:322-34|
|Miyake, Makito; Lawton, Adrienne; Dai, Yunfeng et al. (2014) Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer. BMC Cancer 14:86|
|Gomes-Giacoia, Evan; Miyake, Makito; Goodison, Steve et al. (2014) Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One 9:e96705|
|Chen, Li-Mei; Chang, Myron; Dai, Yunfeng et al. (2014) External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. Cancer Epidemiol Biomarkers Prev 23:1804-12|
Urquidi, Virginia; Goodison, Steve; Rosser, Charles J (2013) Diagnostic Potential of Urinary
|Miyake, Makito; Ross, Shanti; Lawton, Adrienne et al. (2013) Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. BMC Urol 13:42|
|Goodison, Steve; Rosser, Charles J; Urquidi, Virginia (2013) Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol Diagn Ther 17:71-84|
Showing the most recent 10 out of 37 publications